Loading asset research
Nuvectis Pharma Inc. Common Stock
NVCTNasdaq · USD · StocksQuote as of · Exchange session not verified$24.04
+6.89%
Today
NVCT
Loading 1D prices…
Market cap
$783.1M
Volume
221.1K
52w high
$29.2752w low
$5.55Company profile
Nuvectis Pharma Inc. Common Stock
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Fort Lee, NJ, United States
Employees
16
Fiscal year end
1231
CIK
1875558
Session & valuation
Open$22.96
Previous close$22.49
Day high$24.24
Day low$22.28
30-day avg. volume202.3K
Outstanding shares32.6M
Diluted EPS-$1.32
Latest annual period
P/E (trailing)-18.21
P/E (forward)-24.99
Price / book70.56
Beta-0.26
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. Common Stock | $783.1M | $7.8M | -829.58% | -$0.53 | -3.45% | Buy |
| CYRXCryoPort Inc. Common Stock | $787.6M | $176.2M | +44.44% | $1.40 | +1.83% | Buy |
| PHARPharming Group N.V. ADS each representing 10 ordinary shares | $793.4M | $376.1M | +0.76% | $0.04 | +3.75% | Buy |
| SLNSilence Therapeutics Plc American Depository Share | $809.2M | $559K | -15851.52% | -$0.63 | -2.03% | Buy |
| CLYMClimb Bio Inc. Common Stock | $818.5M | $0.00 | — | -$0.88 | -4.85% | Buy |